On March 11, 2019 Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, reported that founder and Chief Executive Officer Dr. David Portman will present at the Boston Oncology Investor Conference (Press release, Sermonix Pharmaceuticals, MAR 11, 2019, View Source [SID1234534397]). Dr. Portman will discuss the Phase 2 study of its lead investigational drug, lasofoxifene, and the drug’s potential as a novel precision medicine treatment for metastatic breast cancer patients with an ESR1 mutation identified through a liquid biopsy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Portman will speak at 6 p.m. on Thursday, March 14. The conference, held at McDermott Will & Emery law firm, 28 State Street in Boston, is organized by the National Foundation for Cancer Research, OneMedMarket and the Altru Institute.
About Lasofoxifene
Lasofoxifene is an investigational, nonsteroidal selective estrogen receptor modulator (SERM), which Sermonix licensed from Ligand Pharmaceuticals Inc. (NASDAQ: LGND) and has been studied in previous comprehensive Phase 1-3 non-oncology clinical trials in more than 15,000 postmenopausal women worldwide. Lasofoxifene’s binding affinity and activity in mutations of the estrogen receptor could potentially hold promise for patients who have acquired endocrine resistance and ESR1 mutations, a common mutation in the metastatic setting and an area of high unmet medical need. Lasofoxifene’s novel activity in ESR1 mutations was recently discovered and Sermonix has exclusive rights to develop and commercialize it in this area. A potent, well-characterized and bioavailable SERM, lasofoxifene, if approved, could play a critical role in the personalized treatment of advanced ER+ breast cancer.